^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

HPV-T

i
Other names: HPV-T
Associations
Trials
Company:
BGI Group
Drug class:
HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor
Associations
Trials
5ms
T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector. (PubMed, NPJ Vaccines)
Here, we first established that anti-vector immunity induced by Lenti-HPV-07 prime has no impact on the efficacy of a homologous boost to amplify anti-HPV T-cell immunity. We then demonstrated that the effector functions of such Lenti-HPV-07-induced T cells synergize with anti-checkpoint inhibitory treatments by systemic administration of anti-TIM3 or anti-NKG2A monoclonal antibodies. While Lenti-HPV-07 is about to enter a Phase I/IIa clinical trial, these results will help better elucidate its mode of action in immunotherapy against established HPV-mediated malignancies.
Journal • Viral vector
|
CD8 (cluster of differentiation 8) • KLRC1 (Killer Cell Lectin Like Receptor C1)
|
HPV-T
11ms
Preferential Expansion of HPV16 E1-Specific T Cells from Healthy Donors' PBMCs after Ex Vivo Immunization with an E1E2E6E7 Fusion Antigen. (PubMed, Cancers (Basel))
Therapeutic HPV vaccines in clinical development show great promise in improving outcomes for patients who mount an anti-HPV T-cell response; however, far from all patients elicit a sufficient immunological response...We suggest that this assay can be a valuable translational tool to complement the known animal models, not only for HPV therapeutic vaccines, and supports the use of E1 as an immunotherapeutic target. Nevertheless, the findings reported here need to be validated in a larger number of donors and preferably in patient samples.
Preclinical • Journal
|
TRIP13 (Thyroid Hormone Receptor Interactor 13)
|
HPV-T
1year
Skin-Grafting and Dendritic Cell "Boosted" Humanized Mouse Models Allow the Pre-Clinical Evaluation of Therapeutic Cancer Vaccines. (PubMed, Cells)
In conclusion, we successfully established two humanized mouse models that exhibited strong antigen-specific responses and demonstrated tumor regression following vaccination. These models serve as valuable platforms for assessing the efficacy of therapeutic cancer vaccines targeting HPV16-dysplastic skin and diverse tumor antigens specifically delivered to CD141 DCs.
Preclinical • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • HLA-A (Major Histocompatibility Complex, Class I, A)
|
HLA-A*02
|
HPV-T
over1year
New P1 trial • Metastases
|
HPV-T